
Managing Rash, Stomatitis, and Other Toxicities in HR+/HER2-Negative Advanced Breast Cancer
Dr. Paolo Tarantino discusses the management of worsening treatment-related toxicities in the patient receiving capivasertib plus fulvestrant.
Episodes in this series

Dr. Paolo Tarantino discusses the management of worsening treatment-related toxicities in the patient receiving capivasertib plus fulvestrant. After 6 weeks of treatment, the patient's rash progresses to grade 3, involving the trunk and upper extremities and causing discomfort. He describes involving dermatology and using systemic corticosteroids in addition to topical treatment to improve the reaction. Given the severity of the rash, he recommends reducing the capivasertib dose from 400 mg to 320 mg twice daily while maintaining the 4-days-on, 3-days-off schedule. He also addresses the development of stomatitis and the role of oral care and steroid-containing mouthwashes in its management. Dr. Tarantino reviews broader strategies for managing cutaneous reactions, diarrhea, and stomatitis, including prophylactic antihistamines, loperamide, dietary adjustments, and dose modification when appropriate. He emphasizes patient education and multidisciplinary care involving nursing, pharmacy, dermatology, and endocrinology. He explains that treatment interruptions and dose reductions can help individualize therapy, manage adverse events, and support continued treatment while maintaining disease control and quality of life.
Related to this article








